JC&P Life Science Partner, Les Iscles, 04300 Forcalquier, France.
Boehringer Ingelheim Animal Health, Centre de Recherche de Saint-Vulbas, Parc Industriel de la Plaine de l'Ain, 805 Allée des Cyprès, 01150 Saint-Vulbas, France.
Comp Immunol Microbiol Infect Dis. 2022 Jul;86:101803. doi: 10.1016/j.cimid.2022.101803. Epub 2022 Apr 2.
In many countries, vaccination programs still require dogs to be vaccinated against rabies in addition to Canine distemper virus (CDV), adenovirus (CAV), parvovirus (CPV), parainfluenza virus (CPiV), Leptospira (L) or Canine coronavirus (CCV= Cv). Few vaccines containing all these antigens are commercially available and, unless compatibility between the vaccines was demonstrated, concurrent administration of a DAPPi-L(Cv) vaccine and a vaccine against rabies should not be recommended. This may be of concern for practitioners who wish to vaccinate dogs with all components on the same day. This study aimed at evaluating immunological compatibility between a monovalent rabies vaccine (Rabisin™) and two large combination vaccines against CDV, CAV, CPV, CPiV with 2 leptospira components +Cv (Recombitek® C6/Cv) or with 4 Leptospira components (Recombitek® C8), when injected concomitantly at two separate injection sites. Fourteen days after administration of the rabies vaccine, with or without concomitant administration of combo vaccines, all dogs had seroconverted against rabies and maintained protective titers over the duration of the study. In addition, 100% of the puppies vaccinated with one or the other combo vaccines seroconverted against CDV, CAV, CPV, CPiV (CCV) and Leptospira, whatever the vaccination group. Lack of immunological interference between Rabisin™ and all components of the Recombitek® C6/Cv or Recombitek® C8 Combo vaccines was demonstrated by non-inferiority analysis, except for CDV in the Recombitek®C8+ Rabisin™ group. Based on these results, a concomitant administration of Rabisin™ with Recombitek® C6/Cv or Recombitek® C8 can be recommended in daily practice, which can be essential for facilitating vaccination compliance.
在许多国家,除了犬瘟热病毒(CDV)、腺病毒(CAV)、细小病毒(CPV)、副流感病毒(CPiV)、钩端螺旋体(L)或犬冠状病毒(CCV=Cv)之外,犬类疫苗接种计划仍需要给狗接种狂犬病疫苗。目前市面上很少有包含所有这些抗原的疫苗,除非证明疫苗之间具有兼容性,否则不建议同时接种 DAPPi-L(Cv)疫苗和狂犬病疫苗。这可能会让那些希望在同一天给狗接种所有疫苗的兽医感到担忧。本研究旨在评估单价狂犬病疫苗(Rabisin™)与两种针对 CDV、CAV、CPV、CPiV 的大型组合疫苗(含 2 种钩端螺旋体成分+CCV[Recombitek® C6/Cv]或 4 种钩端螺旋体成分[Recombitek® C8])在两个不同部位同时注射时的免疫兼容性。在接种狂犬病疫苗 14 天后,无论是否同时接种联合疫苗,所有犬只均针对狂犬病产生了血清转化,并在研究期间维持了保护性滴度。此外,无论接种的是哪种联合疫苗,100%的幼犬均针对 CDV、CAV、CPV、CPiV(CCV)和钩端螺旋体产生了血清转化。非劣效性分析表明,Rabisin™与 Recombitek® C6/Cv 或 Recombitek® C8 联合疫苗的所有成分之间不存在免疫干扰,除了 Recombitek® C8+Rabisin™组中的 CDV 抗体。基于这些结果,可以在日常实践中推荐同时使用 Rabisin™和 Recombitek® C6/Cv 或 Recombitek® C8,这对于促进疫苗接种的依从性至关重要。